Advertisement
Drug Discovery
Subscribe to Drug Discovery

The Lead

NIH Begins Early Human Clinical Trial of New Ebola Vaccine

October 22, 2014 2:00 pm | News | Comments

Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland. Read more...                

UNC Researchers Found New Characters In Cancer Cells

October 22, 2014 1:47 pm | News | Comments

UNC School of Medicine researchers have pinpointed a set of intriguing characteristics in a...

Taiho Receives FDA Fast Track for Cancer Treatment

October 22, 2014 1:14 pm | News | Comments

Taiho Oncology Inc. announced that the FDA...

Oramed Gets Positive Data From Oral Insulin Trial

October 22, 2014 10:03 am | News | Comments

Oramed Pharmaceuticals Inc., a clinical-stage...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Neurocrine Announces Phase 3 Study for Inhibitor

October 21, 2014 2:40 pm | News | Comments

Neurocrine Biosciences Inc. announced that it has initiated a Phase 3 clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854.  Read more...                    

Researchers Demonstrate Advances in Creating Blood Cancer Treatment

October 21, 2014 2:33 pm | News | Comments

Researchers at NYU Langone Medical Center and elsewhere said that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. Read more...    

Lilly's Diabetes Treatment Receives NDA

October 21, 2014 2:19 pm | News | Comments

FDA has accepted the filing of a NDA for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, an investigational compound being studied for the treatment of adults with type 2 diabetes (T2D). Read more...       

Advertisement

Once CD8 T Cells Take on One Virus, They'll Fight Others Too

October 21, 2014 2:02 pm | News | Comments

Scientists think of CD8 T cells as long-lived cells that become tuned to fight just one pathogen, but a study finds that once CD8 T cells fight one pathogen, they also join the body's "innate" immune system, ready to answer the calls of the cytokine signals that are set off by a wide variety of infections. Read more...

Supercomputers Link Proteins to Drug Side Effects

October 21, 2014 1:46 pm | News | Comments

Lawrence Livermore National Laboratory researchers have discovered a high-tech method of using supercomputers to identify proteins that cause medications to have certain adverse drug reactions (ADR) or side effects. Read more...         

RegeneRx Proceeds With Phase 3 Eye Drop Study

October 21, 2014 10:43 am | News | Comments

RegeneRx announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate RGN-259 preservative-free eye drops for the treatment of patients with neurotrophic keratopathy (NK), an orphan disease of the cornea. Read more...

Boehringer Ingelheim Initiates Phase 3 Cancer Study

October 21, 2014 10:34 am | News | Comments

Boehringer Ingelheim announced enrollment of the first patient in a new global Phase 3 study in patients with mCRC. Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed each year. Read more...

New Class of Drugs Shows Promise for Treating Chronic Diarrhea

October 21, 2014 10:23 am | News | Comments

A pilot study testing a new type of drug in patients with chronic diarrhea has shown promising effects on reducing their symptoms. Read more...                                    

Advertisement

Scientists Take Step Toward Drug to Treat Norovirus Bug

October 21, 2014 10:03 am | News | Comments

An experimental drug currently being trialed for influenza and Ebola viruses could have a new target: norovirus, often known as the winter vomiting virus. Read more...                                

Embryonic Stem Cells in Trial for Diabetes

October 20, 2014 4:08 pm | by Cynthia Fox, Science Editor | Articles | Comments

As San Diego’s ViaCyte was in the midst of launching the first FDA-approved embryonic stem (ES) cell clinical trial for diabetes last week, Boston’s Harvard University reported that beta cells from ES cells “cured” diabetic mouse-models. Read more...

BioPontis Alliance, HNF Partner to Develop Treatments for CMT

October 20, 2014 2:29 pm | News | Comments

BioPontis Alliance for Rare Disease and the Hereditary Neuropathy Foundation (HNF), both philanthropies, announced the creation of a joint venture to develop drug candidates for the treatment of the rare disease known as Charcot- Marie-Tooth (CMT) Disease. Read more... 

Lab-Developed Intestinal Organoids Form Mature Human Tissue in Mice

October 20, 2014 2:19 pm | News | Comments

Researchers have successfully transplanted “organoids” of functioning human intestinal tissue grown from pluripotent stem cells in a lab dish into mice – creating an unprecedented model for studying diseases of the intestine. Read more...

Revalesio’s Drug Has Potential to Treat Alzheimer’s Disease

October 20, 2014 12:07 pm | News | Comments

Revalesio Corporation and Rush University Medical Center’s Department of Neurological Sciences published findings from two research studies that demonstrate the potential for RNS60 to treat Alzheimer’s disease and other forms of dementia by protecting neuronal function, restoring neuronal connections and promoting neuronal plasticity. Read more...

Advertisement

Taiho Receives FDA Fast Track Designation for Colorectal Cancer Drug

October 20, 2014 11:55 am | News | Comments

Taiho Oncology announced that the FDA granted Fast Track designation for TAS-102, an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer (mCRC), and that the company has initiated a rolling NDA submission to the FDA. Read more...

Metabolic Genetics Research Paves Way to Treating Diabetes, Obesity

October 20, 2014 11:39 am | News | Comments

Breaking down complex conditions such as Type 2 Diabetes and obesity into the specific metabolic proteins and processes that underlie them offers a new approach to studying the genetics of these diseases and how they are interrelated. Read more...

Clanotech Receives Orphan Drug Designation in the EU

October 20, 2014 10:48 am | News | Comments

Clanotech AB announced that its anti-fibrotic and anti-angiogenic candidate drug CLT-28643 received orphan drug designation by the European Medicines Agency (EMA) for prevention of scarring post glaucoma filtration surgery.  Read more...

Sanofi, Regeneron Announce Phase 3 Study of Atopic Dermatitis Drug

October 20, 2014 10:32 am | News | Comments

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. Read more..

Takeda, Orexigen Announce Availability of Weight-Management Drug

October 20, 2014 10:25 am | News | Comments

Takeda and Orexigen jointly announced that Contrave (naltrexone HCI and bupropion HCI) extended-release tablets are now available to patients by prescription in pharmacies across the United States. Read more...                 

Drug Restores Pleasure-Seeking Ahead of Other Antidepressant Effects

October 20, 2014 10:14 am | News | Comments

A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of — and ahead of — its other antidepressant effects, in an NIH trial. Within 40 minutes after a single infusion of ketamine, treatment-resistant depressed bipolar disorder patients experienced a reversal of a key symptom — loss of interest in pleasurable activities — which lasted up to 14 days. Read more...

AbbVie Announces Results for HS Treatment

October 17, 2014 1:21 pm | News | Comments

AbbVie announced new results from PIONEER 2, a pivotal Phase 3 study, demonstrating the effect of Humira (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. Read more...

UCSF, CDRD Sign Drug Development Agreement

October 17, 2014 1:06 pm | News | Comments

UCSFo and CDRD, a non-profit drug development center headquartered in Vancouver, Canada, announced a collaborative affiliation to identify potential medications and develop them to the stage where they are commercially attractive to private sector partners. Read more...

Pharmacyclics' Non-Chemo Treatment Approved in Europe

October 17, 2014 10:54 am | News | Comments

Pharmacyclics Inc. announced that the European Commission (EC) has granted marketing approval for Imbruvica (ibrutinib) throughout the 28 member states of the European Union (EU). Imbruvica, a first-in-class, oral, once-daily, non-chemotherapy treatment, now is approved to be marketed in Europe. Read more...

A Novel Approach to Alzheimer’s Disease

October 17, 2014 9:57 am | by Daniel L. Alkon, M.D.,Chief Scientific Officer, Neurotrope Inc. and Toyota Chair in Neurodegenerative Disease, Scientific Director and Professor, Blanchette Rockefeller Neurosciences Institute | Articles | Comments

Alzheimer's disease (AD) afflicts more than 5 million people in the U.S. and 40 million worldwide, generating annual healthcare costs that exceed $200 billion in the U.S. and $600 billion globally. By 2050, AD is expected to strike more than 115 million patients per year, according to the Alzheimer’s Association. Read more...

Big Step in Battling Bladder Cancer

October 16, 2014 3:06 pm | News | Comments

The millions of people worldwide who suffer from the painful bladder disease known as interstitial cystitis (IC) may soon have a better, long-term treatment option, thanks to a controlled-release, implantable device invented by MIT researchers. Read more...

Big Step in Battling Bladder Disease

October 16, 2014 1:33 pm | News | Comments

Novel device that stays in the bladder and slowly releases drugs sells to pharmaceutical giant. Read more...                                                             

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading